Top Markets
#1 Siren Siren +36.83%
#2 Wiki Cat Wiki Cat +27.76%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.44%
#4 Gnosis Gnosis +22.36%
#5 Bridged Wrapped stETH (Gnosis) Bridged Wrapped stETH (Gnosis) +21.58%
#6 Velvet Velvet +19.46%
#7 The Grays Currency The Grays Currency +17.02%
#8 PulseChain PulseChain +16.72%
#9 Janction Janction +16.09%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.88%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
Organicell Regenerative Medicine, Inc. Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc.

OCEL
Rank in Stocks #31534
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical... Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.
Share Price
$1.77
Last synced: 2024-04-02
Market Cap
$12.89M
Change (1 day)
-11.50%
Change (1 year)
0.00%
Country
US
Trade Organicell Regenerative Medicine, Inc. (OCEL)

Category

Healthcare
P/E ratio for Organicell Regenerative Medicine, Inc. (OCEL)
P/E ratio as of 2026 TTM: 0
According to Organicell Regenerative Medicine, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Organicell Regenerative Medicine, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.